Mesirow Financial Investment Management’s American Express AXP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$23.7M Sell
70,015
-356
-0.5% -$114K 0.37% 64
2026
Q1
$21.3M Buy
70,371
+1,892
+3% +$634K 0.34% 71
2025
Q4
$25.3M Sell
68,479
-6,410
-9% -$2.29M 0.52% 50
2025
Q3
$24.9M Sell
74,889
-723
-1% -$230K 0.45% 60
2025
Q2
$24.1M Sell
75,612
-535
-0.7% -$151K 0.47% 56
2025
Q1
$20.5M Buy
76,147
+880
+1% +$260K 0.4% 68
2024
Q4
$22.3M Buy
75,267
+75
+0.1% +$21.5K 0.44% 57
2024
Q3
$20.4M Buy
75,192
+450
+0.6% +$112K 0.39% 66
2024
Q2
$17.3M Buy
74,742
+1,944
+3% +$450K 0.39% 65
2024
Q1
$16.6M Buy
72,798
+3,530
+5% +$732K 0.38% 68
2023
Q4
$8.96M Buy
+69,268
New +$11.2M 0.33% 70

Other funds holding AXP

Mesirow Financial Investment Management's AXP Position: Q2 2026 in Review

Mesirow Financial Investment Management reduced its American Express (AXP) stake by 0.51% in Q2 2026, selling an estimated $114K and leaving 70,015 shares worth $23.7M. The position accounts for 0.37% of the portfolio, ranked #64.

Mesirow Financial Investment Management first reported a position in AXP in Q4 2023 and has held it in 11 quarters since. The position peaked at $25.3M in Q4 2025. 2,992 funds tracked by Wall St. Rank hold AXP as of Q2 2026.

  • Mesirow Financial Investment Management held 70,015 shares of American Express worth $23.7M as of Q2 2026.
  • Mesirow Financial Investment Management sold 356 American Express shares in Q2 2026, an estimated $114K.
  • American Express made up 0.37% of Mesirow Financial Investment Management's portfolio in Q2 2026, its #64 holding.
  • Mesirow Financial Investment Management first reported a position in American Express in Q4 2023 and has held it in 11 quarters since.
  • Mesirow Financial Investment Management's American Express position peaked at $25.3M in Q4 2025.
  • 2,992 funds tracked by Wall St. Rank held American Express as of Q2 2026.

Based on Mesirow Financial Investment Management's 13F filing for Q2 2026, filed 22 Jul 2026.